You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Moodys
McKinsey
Harvard Business School
McKesson
Merck
Dow

Last Updated: September 30, 2020

DrugPatentWatch Database Preview

Details for Patent: 8,969,377

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,969,377 protect, and when does it expire?

Patent 8,969,377 protects IBSRELA and is included in one NDA.

This patent has thirty-four patent family members in twenty-one countries.

Summary for Patent: 8,969,377
Title:Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
Abstract: The present disclosure is directed to compounds of the structure (X): ##STR00001## wherein: n is 2 or 3; NHE has the structure ##STR00002## wherein: R.sup.1 is H or --SO.sub.2--NR.sub.7R.sub.8--; R.sup.2 is selected from H, --NR.sub.7(CO)R.sub.8, --SO.sub.2--NR.sub.7R.sub.8-- and --NR.sub.7R.sub.8; R.sup.3 is hydrogen; R.sup.7 is hydrogen; R.sup.8 is a bond linking to L; L is a polyalkylene glycol linker; and Core has the following structure: ##STR00003## wherein: X is selected from the group consisting of a bond, --O--, --NH--, NHC(.dbd.O)--, --NHC(.dbd.O)NH-- and --NHSO.sub.2--; and Y is selected from the group consisting of a bond, optionally substituted C.sub.1-6 alkylene, optionally substituted benzene, pyridinyl, a polyethylene glycol linker and --(CH.sub.2).sub.1-6O(CH.sub.2).sub.1-6--, and methods of using such compounds for the treatment of irritable bowel syndrome, chronic kidney disease and end-stage renal disease.
Inventor(s): Bell; Noah (Fremont, CA), Carreras; Christopher (Fremont, CA), Charmot; Dominique (Fremont, CA), Jacobs; Jeffrey W (Fremont, CA), Leadbetter; Michael Robert (Fremont, CA), Navre; Marc (Fremont, CA)
Assignee: Ardelyx, Inc. (Fremont, CA)
Application Number:13/804,752
Patent Claim Types:
see list of patent claims
Composition; Compound;

Drugs Protected by US Patent 8,969,377

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Ardelyx Inc IBSRELA tenapanor hydrochloride TABLET;ORAL 211801-001 Sep 12, 2019 DISCN Yes No   Start Trial   Start Trial Y Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Dow
McKinsey
Medtronic
Colorcon
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.